Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Viridian Therapeutics reported positive topline data ...

“Over the past few years, with the advent of pharmaceutical therapy for thyroid eye disease, it’s a little more in the forefront. With the marketing and ads on TV, it’s become more commonly discussed, ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a clinical study titled A ...

People with thyroid eye disease receiving infusions of the insulin-like growth factor-1 receptor veligrotug report improved ...

Nearly 2 years after their final infusion with the IGF-IR inhibitor teprotumumab (Tepezza), 82% of patients with thyroid eye disease did not need further treatment for their symptoms, revealed ...

Doses of Tepezza are given by an intravenous infusion through a blood vessel in your arm. This infusion is usually given at a hospital, health care provider’s office, or infusion center. Sometimes you ...

“In our study, Black patients with TED presented with fewer clinical exam features based on current classification guidelines, but had longer follow-up and underwent similar treatments as White ...

Thyroid eye disease (TED) is complicated, with symptoms that can vary from person to person. It’s not widely understood — even by healthcare providers in some cases. Research indicates that it’s ...